⌘K
t
On 21 October 2024, Creo Medical Group plc announced that its Non-Executive Chairman, Kevin Crofton, and Chief Financial Officer, Richard Rees, acquired new ordinary shares. These acquisitions were made at an issue price of 24 pence per ordinary share as part of a recent fundraising on the London Stock Exchange. Kevin Crofton purchased 2,916,666 shares, resulting in 0.87% of voting rights, and Richard Rees purchased 208,333 shares, resulting in 0.74% of voting rights post-transaction.
| Date | 21 Oct 2024 |
| Time | 10:06:30 |
| Category | Director/PDMR dealings |
| ID | 9613I |
LEI: 213800H188ZDCWWXFA21
21 October 2024
Creo Medical Group plc
("Creo" or the "Company")
Director/PDMR Share Dealings
Further to the announcements made on 30 September 2024 and 18 October 2024, and pursuant to the recent fundraising, the Company confirms that the following directors of the Company have acquired New Ordinary Shares at the Issue Price of 24 pence per Ordinary Share as follows:
|
Director/PDMR Name |
No. of New Ordinary Shares Acquired |
Resultant Shareholding post transaction |
% of voting rights post transaction |
|
Kevin Crofton |
2,916,666 |
3,566,666 |
0.87% |
|
Richard Rees |
208,333 |
3,036,540 |
0.74% |
|
|
||||||||||||||||||||||
|
|
|
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Kevin Crofton |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Non-Executive Chairman |
|
|
b) |
Initial notification/Amendment |
Initial Notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Creo Medical Group plc |
|
|
b) |
LEI |
213800H188ZDCWWXFA21 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of £0.001 each |
|
|
|
Identification code |
GB00BZ1BLL44 |
|
|
b) |
Nature of the transaction |
Purchase of Ordinary Shares |
|
|
c) |
Price(s) and volumes(s) |
Price(s) |
Volume(s) |
|
£0.24 |
2,916,666 |
||
|
d) |
Aggregated information |
N/A single transaction |
|
|
|
Aggregated volume |
N/A single transaction |
|
|
|
Price |
N/A single transaction |
|
|
e) |
Date of the transaction |
21 October 2024 |
|
|
f) |
Place of the transaction |
London Stock Exchange |
|
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Richard Rees |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Chief Financial Officer |
|
|
b) |
Initial notification/Amendment |
Initial Notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Creo Medical Group plc |
|
|
b) |
LEI |
213800H188ZDCWWXFA21 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of £0.001 each |
|
|
|
Identification code |
GB00BZ1BLL44 |
|
|
b) |
Nature of the transaction |
Purchase of Ordinary Shares |
|
|
c) |
Price(s) and volumes(s) |
Price(s) |
Volume(s) |
|
£0.24 |
208,333 |
||
|
d) |
Aggregated information |
N/A single transaction |
|
|
|
Aggregated volume |
N/A single transaction |
|
|
|
Price |
N/A single transaction |
|
|
e) |
Date of the transaction |
21 October 2024 |
|
|
f) |
Place of the transaction |
London Stock Exchange |
|